Antoinette Gawin: Turning Innovation Into Action for America’s Blood Supply
Antoinette Gawin, President and Chief Executive Officer at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
”Behind every blood shortage statistic is a patient waiting for care.
As the American Red Cross declares its second-ever national blood supply crisis, blood centers need every available tool to help strengthen operations and serve patients.
The FDA’s decision to reduce review timelines for future implementations of the Reveos Automated Blood Collection System from 12 months or longer to as little as 30 days is an important step forward.
Blood can’t wait. Faster access to innovation helps blood centers spend less time navigating approvals and more time supporting the communities that depend on them.
I’m grateful to the FDA, AABB, America’s Blood Centers, and everyone who helped make this progress possible.”
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments